Unexpected responses to EGFR inhibition in NSCLC

The presence of activating mutations of the epidermal growth factor receptor (EGFR)-gene identifies a distinct and clinically relevant molecular subset of non-small-cell lung cancer. It is now well demonstrated that EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are superior to stand...

Descripción completa

Detalles Bibliográficos
Autores principales: Stella, Giulia M., Valizia, Claudio, Zorzetto, Michele, Inghilleri, Simona, Valentini, Adele, Dore, Roberto, Colombo, Sara, Valentino, Francesco, Orlandoni, Giulio, Morbini, Patrizia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681892/
https://www.ncbi.nlm.nih.gov/pubmed/26744648
http://dx.doi.org/10.1016/j.rmcr.2015.06.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681892/
https://www.ncbi.nlm.nih.gov/pubmed/26744648
http://dx.doi.org/10.1016/j.rmcr.2015.06.006

Ejemplares similares